HASTINGS DAVID C (Chief Financial Officer) received a stock award from ARBUTUS BIOPHARMA CORP
Compensation award — not an open‑market transaction. Less informative as a directional signal.
A · 1 award
Filed: 2/19/2025ACC: 0001447028-25-000050
Officer· Chief Financial Officer
Since Mar 2019
+455.90K
Net shares
Net buyer
$0.00
Total acquired
0
Open market trades
0B · 0S
2
Total transactions
455.90K acquired
Non-Derivative Transactions1
Common Shares
Direct
Shares
+90.10K
Price / share
—
Trade value
—
% of position
56.4%
2/14/2025
159.72K→249.82K
Total
Net shares
+90.10K
Net value
$0.00
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Shares Direct | 2/14/2025 | A · Award | +90.10K | — | — | 56.4% | 159.72K | 249.82K |
| Total | +90.10K | $0.00 | ||||||
Derivative Transactions1
Stock Option (Right to Buy)
Direct
Converts to
Common Shares
365.80K shares
Shares
+365.80K
Strike price
3.29
Held after
365.80K
Exercisable
—
2/14/2025
| Security | Converts To | Date | Type | Shares | Strike Price | Exercisable | Held After |
|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) Direct | Common Shares365.80K shares | 2/14/2025 | A · Award | +365.80K | 3.29 | — | 365.80K |